41条结果 每页10条
专家PPT:ARDS全球新定义
专家PPT:ARDS全球新定义

文章来源:免疫炎症事业部中央市场部

汇伦医药 袁芳 2024-10-14 39 0 公开
科室会PPT:希为纳®在心外科的应用
科室会PPT:希为纳®在心外科的应用

文章来源:免疫炎症事业部中央市场部

汇伦医药 袁芳 2024-10-14 47 0 公开
科室会PPT:希为纳®产品信息介绍
科室会PPT:希为纳®产品信息介绍

文章来源:免疫炎症事业部中央市场部

汇伦医药 袁芳 2024-10-14 135 0 公开
急性A型主动脉夹层术前低氧血症患者围术期应用西维来司他钠缩短术后有创机械通气时间的临床预试验
急性A型主动脉夹层术前低氧血症患者围术期应用西维来司他钠缩短术后有创机械通气时间的临床预试验

摘要信息:研究目标: 评价急性A型主动脉夹层术前低氧血症(PaO2/FiO2≤300mmHg)患者术中应用西维来司他钠缩短术后有创机械通气的有效性和安全性。 研究设计类型、原则与实施方法 总体设计 单中心、安慰剂、双盲、随机平行对照研究。 本研究计划纳入30例急性A型主动脉夹层术前低氧血症(PaO2/FiO2≤300mmHg)患者,受试者按照1:1的比例随机分配至试验组或对照组,分别接受西维来司他钠组与安慰剂组,评价西维来司他钠缩短术后有创机械通气时间。 评价指标 主要终点指标 有创机械通气时间(小时):从有创机械通气开始至第一次成功拔除气管插管的持续时间。第一次成功拔除气管插管定义为拔除气管插管后患者能够自主呼吸超过48小时。 次要终点指标 全部有创机械通气情况(模式和时间)、全部无创机械通气情况(模式和时间)、全部高流量吸氧情况(流量和时间)。 氧合指数及其曲线下面积、PaO2/FiO2≤300mmHg持续时间(小时)、急性肺损伤、呼吸机相关肺炎、Murray肺损伤评分。 术后ICU滞留时间(天)、术后住院时间(天)、APACHE II评分、SOFA评分。 围术期死亡、脑卒中、截瘫、暂时性神经系统功能不全、癫痫、急性肾损伤、感染、心律失常、心脏骤停、急性胰腺炎、消化道出血、术中、术后输注血制品的情况(种类和数量)。 血流动力学指标、实验室检查指标、影像学指标、卫生经济学指标。 28天无呼吸机时间(天)、术后28天的全因死亡、28天内氧疗、无创机械通气、有创机械通气、俯卧位通气、吸入一氧化碳治疗。 安全性指标 急性肝功能损伤、黄疸、白细胞减少、中性粒细胞减少、血小板减少等不良事件发生情况。 实验室检查(血常规、血生化)

汇伦医药 邹文成 2024-09-05 214 0 公开
A neutrophil elastase inhibitor, sivelestat, improved respiratory and cardiac function in pediatric cardiovascular surgery with cardiopulmonary bypass
A neutrophil elastase inhibitor, sivelestat, improved respiratory and cardiac function in pediatric cardiovascular surgery with cardiopulmonary bypass

摘要信息:Purpose:Several reports indicate that a neutrophil elastase inhibitor, sivelestat, may have prophylactic efficacy against a systemic inflammatory response after cardiovascular surgery with cardiopulmonary bypass (CPB). We evaluated the clinical pulmonary and cardiac effects of sivelestat. Methods:We performed a retrospective study of 25 pediatric patients who underwent elective cardiovascular surgery with CPB for ventricular septal defect with pulmonary hypertension. Ten patients received 0.2 mg x kg(-1) x h(-1) sivelestat; the other is patients were the control group. There were no significant differences in demographic characteristics between the two groups. The P(a)O(2)/fractional inspired oxygen (F(I)O(2); P/F) ratio, the respiratory index (RI), and the fractional area change (FAC) of the left ventricle (LV) in the postoperative course were measured. Results:The P/F ratio was higher in the sivelestat group compared with the control group and there were significant differences between the two groups immediately after weaning form CPB, and at 12 h after weaning from CPB (P < 0.05). The RI was lower in the sivelestat group compared with the control group and there were significant differences between the two groups at immediately after weaning from CPB, and at 6 h and 12 h after CPB (P < 0.05). The FAC of the LV was significantly better in the sivelestat group and there was a significant difference between the two groups on postoperative day (POD) 3 (P < 0.05). Conclusion:We have shown that pediatric patients who underwent cardiovascular surgery with CPB who received sivelestat had a higher P/F ratio, a lower RI, and better FAC of the LV in the postoperative course.

汇伦医药 邹文成 2024-09-05 181 0 公开
Effect of additional preoperative administration of the neutrophil elastase inhibitor sivelestat on perioperative inflammatory response after pediatric heart surgery with cardiopulmonary bypass
Effect of additional preoperative administration of the neutrophil elastase inhibitor sivelestat on perioperative inflammatory response after pediatric heart surgery with cardiopulmonary bypass

摘要信息:Cardiopulmonary bypass (CPB) elicits a systemic inflammatory response. Our previous reports revealed that prophylactic sivelestat administration at CPB initiation suppresses the postoperative acute inflammatory response due to CPB in pediatric cardiac surgery. The purpose of this study was to compare the effects of sivelestat administration before CPB and at CPB initiation in patients undergoing pediatric open-heart surgery. Twenty consecutive patients weighing 5-10 kg and undergoing ventricular septal defect closure with CPB were divided into pre-CPB (n = 10) and control (n = 10) groups. Patients in the pre-CPB group received a 24 h continuous intravenous infusion of 0.2 mg/kg/h sivelestat starting at the induction of anesthesia and an additional 0.1 mg/100 mL during CPB priming. Patients in the control group received a 24-h continuous intravenous infusion of 0.2 mg/kg/h sivelestat starting at the commencement of CPB. Blood samples were tested. Clinical variables including blood loss, water balance, systemic vascular resistance index, and the ratio between partial pressure of oxygen and fraction of inspired oxygen (P/F ratio) were assessed. White blood cell count and neutrophil count as well as C-reactive protein levels were significantly lower in the pre-CPB group according to repeated two-way analysis of variance, whereas platelet count was significantly higher. During CPB, mixed venous oxygen saturation remained significantly higher and lactate levels lower in the pre-CPB group. Postoperative alanine aminotransferase and blood urea nitrogen levels were significantly lower in the pre-CPB group than in the control group. The P/F ratio was significantly higher in the pre-CPB group than in the control group. Fluid load requirement was significantly lower in the pre-CPB group.Administration of sivelestat before CPB initiation is more effective than administration at initiation for the suppression of inflammatory responses due to CPB in pediatric open-heart surgery, with this effect being confirmed by clinical evidence.

汇伦医药 邹文成 2024-09-05 191 0 公开